personalised cancer prevention UK

Protect yourself with personalised cancer prevention

Detect your genetic risks early and get actionable medical advice for prevention to protect your health.

personalised cancer prevention UK

Supported by

One in four women and one in three men will develop cancer in their lifetime. We need to take action early to protect our health.

Next-generation cancer prevention considers your risk profile

Common cancers and related deaths can often be prevented with timely measures. Personalised cancer prevention with genetic risk assessment can give early warning to women and men at risk even if there is no cancer in the family. It guides you towards tailored screening and prevention based on personal risk level.

Personalised breast cancer prevention

  • Breast cancer is the most common cancer in women, affecting 1 in 7 women in their lifetime.
  • 1 in 5 breast cancer cases are diagnosed in women under 50, but screening programme start at age 50. Early prevention is crucial.
  • Genetic risk testing helps to evaluate your risk level and provides a personalised medical prevention plan to reduce your risks.
  • Personalised breast cancer prevention is recommended for all women aged 30 and above to identify higher risks early and start personalised screening programme years before NHS screening programme begins to protect your health. Perfect for health-conscious women, with or without a family history of cancer.
Learn more
personalised prostate cancer prevention for men aged 40+

Personalised prostate cancer prevention

  • Prostate cancer is the most common cancer in men. More than 55 000 new cases of the disease are diagnosed in the UK every year, and around 12 000 men die from prostate cancer each year.
  • About 58% of prostate cancer risk is inherited, even without any visible warning signs such as a family history of cancer.
  • Standard PSA-based screening may miss these high genetic risk cases, as PSA levels can remain normal even when cancer is already developing.
  • Genetic risk testing helps to evaluate your inherited risk and provides a personalised medical prevention plan to reduce your risks.
  • Recommended for men aged 40 and above.
Learn more

Here’s what you’ll learn:

  • What is your genetic risk level for the most common cancer in men and women

  • When should you begin cancer screening, and how often

  • Are there additional measures you can take to lower your risk

  • What proactive measures can you adopt to reduce your likelihood of developing cancer

  • What changes or symptoms should you monitor

  • What should your doctor know

illustration

Powered by Innovative Polygenic Risk Score (PRS)

PRS is an innovative, non-intrusive method for predicting disease risk to enable personalised prevention. The use of PRS genetic tests in clinical practice represents a modern standard of care in personalised medicine, supported by extensive research data and clinical evidence from numerous studies.

Our PRS calculates the combined effect of 2803 genetic variants associated with breast cancer. By combining the PRS with a person’s background (origin, age, and gender), we are able to calculate a person’s risk of developing cancer. Moreover, we provide tailored medical advice to prevent illness or promote early detection.

Approved by doctors and customers

Over 16 000 valuable insights from us

“Breast cancer is a devastating disease that affects too many people – the patients, their families, friends and colleagues. It is a disease that can often be cured if caught early and suitable treatments are prescribed. But what if there was no need for the cure? There was no diagnosis, no before or after breast cancer. What if people could live their lives safe in the knowledge that it would never happen to them.”

Lester Barr, MBE Co-Founder & Honorary President of Prevent Breast Cancer

Developed & supported by leading healthcare professionals

All our services are developed in co-operation with leading oncologists, medical geneticists and bioinformaticians across Europe and the UK.

  • Laura Naylor Founder of The Breast Awareness Clinic; Senior Breast Clinical Nurse Specialist
  • Lester Barr, MBE Co-Founder & Honorary President of Prevent Breast Cancer
  • Prof. Gareth Evans, MB, BS, MD, FRCP, FLSW, FRCOG, ad eundem Consultant Geneticist
  • Peeter Padrik, MD, PhD Oncologist

Fully compliant with all regulatory bodies

Personalised cancer prevention is based on genetic risk tests provided by Antegenes.

✔ CE-marked medical devices (in vitro diagnostics, IVD)
✔ Registered in the UK MHRA Registry and EUDAMED database
✔ Developed using anonymised data from the UK Biobank
✔ Antegenes is ISO 13485 certified
✔ We take your data privacy and protection very seriously

Prevent
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.